Lynne Poole - Concepedia

Author

Lynne Poole

AstraZeneca (United Kingdom)

Also Known As

LYNNE POOLE, Lynne Poole

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United Kingdom)University of the West of Scotland Eli Lilly (United Kingdom)Kanagawa Prefectural Hospital Organization AstraZeneca (United States)

About

Lynne Poole is an author at AstraZeneca (United Kingdom) specializing in medicine, social sciences, and psychiatry.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	465
2	Business	4	4	160
3	Health Sciences	4	4	105
4	Education	1	1	15
5	Law	1	1	32

Lynne Poole

Publications

Citations

H-Index

Page 1

	Year	Citations
Overall Survival with Osimertinib in Resected <i>EGFR</i> -Mutated NSCLC Masahiro Tsuboi, Roy S. Herbst, Thomas John, New England Journal of Medicine	2023	546
Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study Melissa L. Johnson, Byoung Chul Cho, Alexander Luft, Journal of Clinical Oncology	2022	406
Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study Rina Hui, Mustafa Özgüroğlu, Augusto Villegas, The Lancet Oncology	2019	185
Cross-cultural reliability and validity of ADHD assessed by the ADHD Rating Scale in a pan-European study Manfred Döpfner, Hans‐Christoph Steinhausen, David Coghill, European Child & Adolescent Psychiatry AdhdNeuropsychological FunctioningPsychiatryCross-cultural AssessmentPsychology	2006	116
A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit/hyperactivity disorder (ADHD) Suyash Prasad, Valerie Harpin, Lynne Poole, Current Medical Research and Opinion	2007	97
‘A land of milk and honey’? Social policy in Scotland after Devolution Gerry Mooney, Lynne Poole Critical Social Policy ColonialismPublic WelfareSocial ChangePolicy AnalysisSocial Sciences	2004	75
Efficacy and safety of atomoxetine as add-on to psychoeducation in the treatment of attention deficit/hyperactivity disorder Pär Svanborg, Gunilla Thernlund, Per Gustafsson, European Child & Adolescent Psychiatry AdhdAttention Deficit/hyperactivity DisorderPsychiatryAddictionPsychotropic Medication	2009	71
Cost-Effectiveness Analysis of Stratified Versus Stepped Care Strategies for Acute Treatment of Migraine Mark Sculpher, David Millson, D Meddis, PharmacoEconomics Acute TreatmentCost-effectiveness AnalysisHealthcare ValueHealth Care ReimbursementPatient Safety	2002	63
Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study Grazia Dell’Agnello, Dino Maschietto, Carmela Bravaccio, European Neuropsychopharmacology AdhdPsychiatryMedicinePsychotropic MedicationPediatrics	2009	54
Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim, Lung Cancer	2020	54

Page 1